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MaOBJECTIVES This study investigated the prevalence and potential incremental prognostic value of combined free light
chains (cFLCs) in patients recently hospitalized with decompensated heart failure (HF).
BACKGROUND Inﬂammatory pathways are recognized in the pathogenesis and progression of HF. Free light chain (FLC)
elevation is conventionally associated with monoclonal gammopathies, including multiple myeloma. Polyclonal increases in
both kappa and lambda FLCs occur in autoimmune and other chronic inﬂammatory conditions. Recently, a novel assay for
measuring kappa and lambda immunoglobulin FLCs together, knownas combined free light chain (cFLC) hasbeendeveloped.
METHODS Six hundred twenty-eight patients recently hospitalized with decompensated HF were studied. cFLCs were
measured by turbidimetry using an immunoassay. The incremental prognostic value of cFLCs for mortality was evaluated
using Cox proportional hazard models including 22 established predictors of outcome in HF.
RESULTS Of 628 patients, 290 (46%) died during a follow-up of 3.2 1.5 years. Two hundred seventy patients (43%) had
elevated cFLCs. There was a clear gradient in the risk of death according to cFLC quartile, with those in the top quartile
having an unadjusted risk of mortality more than twice that of those in the lowest quartile (hazard ratio: 2.38; p<0.0001).
After multivariable analysis, cFLC remained an independent predictor ofmortality, with an almost 50%higher adjusted risk
for those in the top compared with bottom quartile. Older age, lower body mass index, New York Heart Association clas-
siﬁcation III/IV, previousmyocardial infarction, current smoking and B-type natriuretic peptide, bilirubin, high-sensitivity C-
reactive protein, glycated hemoglobin, and lymphocyte concentrations were also independent predictors of mortality.
CONCLUSIONS cFLCs are an independent predictor of mortality in patients recently hospitalized with decompensated
HF. Further work is required to assess the effects of HF therapies on cFLC concentrations and whether or not directly
targeting this marker of inﬂammation improves prognosis for patients with HF. (J Am Coll Cardiol HF 2015;3:618–25)
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AB BR E V I A T I O N S
AND ACRONYM S
BMI = body mass index
BNP = B-type natriuretic
peptide
cFLC = combined free
light chains
HF = heart failure
hsCRP = high-sensitivity
C-reactive protein
LVEF = left ventricular
ejection fraction
MI = myocardial infarction
NYHA = New York Heart
Association
RDW = red cell distribution
width
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619pathogen-related toxins. When aberrant, this anti-
body response may lead to autoimmune disease.
Immunoglobulins (antibodies) consist of heavy and
light chains with the latter comprising either kappa
or lambda variants. B cells, plasma blasts, and plasma
cells produce surplus light chains; those not bound to
heavy chains can be detected as soluble free light
chains (FLCs) in plasma/serum. FLC elevation is
conventionally associated with monoclonal gammo-
pathies (2–5), including multiple myeloma. Polyclonal
increases in both kappa and lambda FLCs occur in
autoimmune and other chronic inﬂammatory condi-
tions, characterized by chronic B cell maturation,
activation, and consequent increased immunoglob-
ulin production such as rheumatoid arthritis, sys-
temic lupus erythematosus, and chronic obstructive
pulmonary disease (6–8). Conditions impairing FLC
clearance, such as renal or reticuloendothelial system
diseases, may also result in elevation of polyclonal
FLC concentrations (9–12).SEE PAGE 626Traditional methods of measuring excess immu-
noglobulins, such as serum protein electrophoresis or
immunoﬁxation, may not detect minor increases in
serum light chains. More sensitive nephelometric
assays measuring individual kappa and lambda FLC
concentrations have been available for approximately
a decade (13). Recently, a sensitive and novel assay
measuring both kappa and lambda FLCs, referred to
as combined free light chains (cFLCs), has been
developed (14). Using this new assay, we have studied
the prevalence and prognostic value of elevated cFLC
concentrations in HF.
METHODS
Our study complied with the Declaration of Helsinki
and was approved by the Local Ethics Committee. All
patients provided written informed consent.
STUDY DESIGN. The study design is described
elsewhere (15). Brieﬂy, we enrolled 1,003 near-
consecutive patients with decompensated HF from
3 hospitals. HF was deﬁned according to the criteria
of the European Society of Cardiology (16). Eligible
patients were also required to be 18 years of age
or older and to have an elevated B-type natriuretic
peptide (BNP >100 pg/ml). The main exclusion
criteria were primary presentation with myocardial
infarction (MI) and signiﬁcant cognitive impairment
or concurrent systemic disease likely to result in
reduced life expectancy. Attendance for the study
visit was planned 1 month post-discharge. Of 1,003
patients originally enrolled, 648 patients (65%)returned for the study visit. Failure to attend
was due to death (n ¼ 115, 11%), deterioration
in health (n ¼ 73, 7%), or withdrawal of con-
sent (n ¼ 167, 17%).
LABORATORY MEASUREMENTS. Whole blood
was drawn from venipuncture into serum and
plasma vacutainers. Samples were processed
immediately by centrifugation at 3,000 g
for 15 min and serum and plasma fractions
were aliquoted for storage at -80C until
assay. cFLCs were measured by turbidimetry
using the Combylite immunoassay on a
SPAPLUS automated analyzer (The Binding Site
Group Ltd., Birmingham, United Kingdom).
Elevated concentrations of cFLCs were de-
ﬁned as >45.7 mg/l, above the 95% reference
range for the combined kappa and lambda
FLC assays (17). Combylite immunoassay has a limit
of quantiﬁcation of 0.63 mg/l on neat samples, and
assay precision (coefﬁcient of variation) of 5.5%
around the upper reference interval (54 mg/l) (14).
High-sensitivity C-reactive protein (hsCRP) was
assayed using a Siemens immunoassay on a Siemens
BN II nephelometer (Siemens Healthcare Diagnostics
GmbH, Marburg, Germany). Plasma BNP was mea-
sured using an Abbott Architect assay (Abbott Dia-
gnostics, Maidenhead, United Kingdom). cFLCs were
measured by The Binding Site Group Ltd., who sup-
plied the assay results to the study statistician (CH)
but did not have access to any other data and were not
involved in the data analysis. All other biomarker as-
says were performed in local laboratories in Glasgow,
United Kingdom.
LEFT VENTRICULAR EJECTION FRACTION. Left
ventricular ejection fraction (LVEF) was measured by
2-dimensional echocardiography. Analysis was per-
formed ofﬂine, using the biplane method of discs
(modiﬁed Simpson’s rule) by a single operator blin-
ded to patient information. Twenty-six patients had
an incalculable LVEF by this method. Reduced sys-
tolic function was deﬁned as LVEF <50% (18).
FOLLOW-UP. All enrolled patients consented to be
“ﬂagged” with the Information Services Division of
the Scottish Health Service for data on in-hospital and
out-of-hospital deaths, held by the General Register
Ofﬁce for Scotland. The primary outcome measure of
this study was death from any cause.
STATISTICAL ANALYSIS. Differences in clinical char-
acteristics according to quartiles of cFLC concentra-
tion were compared using 1-way analysis of variance
for continuous variables and Fisher’s test for cate-
gorical variables. All continuous variables were trans-
formed as appropriate to normalize their distributions.
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620Survival time was calculated from the date of the
study visit (between January 16, 2007 and March 6,
2009) until death or censoring at August 31, 2012.
Inter-group differences in mortality rates were inves-
tigated using a chi-squared test. Kaplan-Meier sur-
vival curves were constructed to show survival of
patients according to cFLC concentration. Curves
were compared using the log-rank test. The incre-
mental prognostic value of cFLC was evaluated using
Cox proportional hazard models including established
predictors of outcome in HF. These predictors were
prospectively selected from the clinical model derived
by the CHARM investigators (Candesartan in Heart
failure: Assessment of Reduction in Mortality and
morbidity) (19) and routine hematological and bio-
chemical variables predictive of outcome in the sub-
sequent CHARM analyses (20,21). The established
predictors of outcome included: age, sex (men vs.
women), smoking habit (current vs. none or past),
history of HF for more than 2 years, New York Heart
Association (NYHA) functional class (III/IV vs. I/II),
LVEF, medical history (MI, diabetes mellitus, chronic
obstructive pulmonary disease, peripheral arterial
disease), left bundle branch block on electrocardio-
gram, heart rate, systolic blood pressure, body mass
index (BMI), peripheral edema, bilirubin, urate,
creatinine, hemoglobin, glycosylated hemoglobin,
lymphocytes, and red cell distribution width (RDW).
BNP and hsCRP were also included. Restricted cubic
splines with 5 knots were performed on all continuous
variables and the data were log transformed to
improve linearity if splines revealed a non-linear
relationship. Log transformations were all natural
logs, and improvement in linearity was determined by
a combination of inspecting spline plots and an
increased Wald linearity p value (with the null hy-
pothesis being that data are linear). Cutpoints for
continuous biomarkers were determined using sur-
vival receiver-operating characteristic (ROC) curves
using the freely distributed R package Hmisc. All other
statistical analyses were performed using R version
2.15.0 (R Foundation for Statistical Computing,
Vienna, Austria) or SAS version 9.3 (SAS Institute,
Cary, North Carolina), or later versions of these pro-
grams, and a p value <0.05 was considered statisti-
cally signiﬁcant. Model performance and comparison
was assessed using Harrel’s c-statistic (22). The net
reclassiﬁcation index (NRI) (23), adapted for use in
survival models (24), was used to assess if cFLCs
improved the prediction of outcome, in addition to
BNP. For model comparison, c-statistics were gener-
ated using ordinary non-parametric bootstrapping
with 1,000 replicates, and then p values obtained
from paired Student t tests. Internal validation wasperformed by bootstrapping, using Somers’ Dxy rank
correlation as the marker of validation, to evaluate the
predictive performance of the data. No adjustment has
been made for multiple comparisons.
RESULTS
STUDY COHORT AND CLINICAL CHARACTERISTICS
ACCORDING TO cFLC CONCENTRATION. Of 648
patients completing the study, 628 (97%) had cFLC
analysis performed on stored blood samples. The
baseline clinical characteristics of the patients are
summarized in Table 1, for both the overall cohort and
per quartile of cFLC concentration. The mean (SD) age
of the overall cohort was 71  11 years and 367 (58%)
were male. The median (interquartile range) cFLC
concentration was 41.9 (29.5 to 62.2) mg/l. Of 628
patients, 270 (43%) had elevated cFLC concentrations
(deﬁned as >45.7 mg/l) (17).
Patients with an elevated cFLC concentration were
older andmore likely to bemale. A history of HF before
the index hospitalization was more common among
those with increased cFLC concentration and the
presence of peripheral edema at the baseline assess-
mentmore common among thosewith elevated cFLCs.
Patients with an elevated cFLC concentration were
more likely to have a history of hypertension, diabetes
mellitus, and peripheral artery disease. There was no
difference in LVEF according to cFLC concentration
and the use of HFmedications was similar between the
4 groups, although there was a trend towards patients
with lower cFLC concentrations beingmore likely to be
prescribed an angiotensin-converting enzyme inhibi-
tor or angiotensin receptor blocker than those with
higher cFLC concentrations. There was no difference
in blood pressure or heart rate between the groups.
BNP, hsCRP, RDW, urate, and glycosylated hemo-
globin concentrations were higher in patients with
elevated cFLCs. Renal dysfunction, anemia, and lym-
phopenia were also more common in these patients.
The prevalence of rheumatoid arthritis and con-
nective tissue diseases was low in the patients overall
and did not differ according to cFLC concentration.
There were no patients with diagnosed monoclonal
gammopathies (including monoclonal gammopathy
of unknown signiﬁcance, primary systemic amyloid-
osis, multiple myeloma, Waldenstrom macroglobuli-
nemia, and light-chain-deposition disease); these
conditions are conventionally associated with
abnormal amounts of FLCs.
OVERALL SURVIVAL AFTER HOSPITAL ADMISSION
WITH DECOMPENSATED HF. The mean follow-up
was 3.2  1.5 years. Of the 628 patients, 290 (46%)
died during the follow-up period.
TABLE 1 Baseline Characteristics Overall and Stratiﬁed by Quartiles of cFLC Concentration
Overall
(n ¼ 628)
Q1 (<29.5 mg/l)
(n ¼ 157)
Q2 (29.5–41.9 mg/l)
(n ¼ 157)
Q3 (41.9–62.2 mg/l)
(n ¼ 157)
Q4 (>62.2 mg/l)
(n ¼ 157) p Value
Demographic characteristics
Age, yrs 70.8  10.6 66.1  12.2 71.3  10.2 72.6  9.1 73.3  9.3 <0.0001
Male 367  58.4 78  49.7 81  51.6 96  61.1 112  71.3 <0.001
Current smoker 137  21.8 39  24.8 37  23.6 27  17.2 34  21.7 0.372
HF status
Previous diagnosis HF 273  43.5 58  36.9 67  42.7 66  42.0 82  52.2 0.052
HF >2 yrs 194  30.9 40  25.5 48  30.6 51  32.5 55  35.0 0.309
NYHA functional class III/IV (vs. I/II) 208  33.1 40  25.5 55  35.0 56  35.7 57  36.3 0.127
LVEF, % 40.1  12.1 38.7  11.7 41.6  12.6 40.1  12.8 39.9  11.2 0.213
LVEF <50% 466  77.4 123  81.5 109  71.2 114  78.1 120  78.9 0.184
Peripheral edema 421  67.0 82  52.2 99  63.1 112  71.3 128  81.5 <0.0001
Medical history
MI 285  45.5 61  38.9 76  48.4 73  46.5 75  47.8 0.292
Hypertension 404  64.3 82  52.2 106  67.5 102  65.0 114  72.6 0.002
Diabetes mellitus 195  31.1 29  18.5 45  28.7 52  33.1 69  43.9 <0.0001
AF 334  53.2 84  53.5 66  42.0 96  61.1 88  56.1 0.006
COPD 177  28.2 35  22.3 53  33.8 47  29.9 42  26.8 0.141
PAD 102  16.2 11  7.0 26  16.6 29  18.5 36  22.9 <0.001
Rheumatoid arthritis 17  2.7 7  4.5 3  1.9 3  1.9 4  2.5 0.495
Connective tissue disease 12  1.9 3  1.9 5  3.2 1  0.6 3  1.9 0.479
Physiological measurements
HR, beats/min 77.1  15.6 79.0  16.9 77.6  14.8 77.0  16.0 74.8  14.2 0.124
SBP, mm Hg 130.9  23.4 129.2  23.6 131.8  24.2 131.8  22.0 130.9  23.9 0.727
DBP, mm Hg 67.8  13.2 69.3  13.5 67.6  13.3 68.2  12.9 66.1  13.2 0.186
BMI, kg/m2 28.6  6.7 28.5  6.8 28.6  7.0 28.5  6.0 28.9  7.0 0.948
LBBB 120  19.1 37  23.6 28  17.8 28  17.8 27  17.2 0.458
Laboratory measurements
BNP, pg/ml 393 [201-796] 323 [164-697] 364 [188-733] 432 [207-870] 439 [235-926] 0.033
Urea, mmol/l 9.7  5.1 7.2  2.7 8.0  3.3 9.8  4.5 13.8  6.2 <0.0001
Creatinine, mmol/l 117  44 94  21 102  24 118  33 156  57 <0.0001
eGFR, ml/min/1.73 m2 50  17 55  18 53  16 51  17 40  15 <0.0001
eGFR, <60 ml/min/1.73 m2 337  54 41  26.1 68  43.3 95  60.5 133  84.7 <0.0001
eGFR, <30 ml/min/1.73 m2 50  8.0 0  0 4  2.5 8  5.1 38  24.2 <0.0001
Bilirubin, mmol/l 11.6  8.0 11.5  7.2 11.1  7.3 11.9  6.9 11.9  10.0 0.774
hsCRP, mg/l 9.3  13.2 5.3  7.7 7.8  10.9 9.5  11.9 14.7  18.3 <0.0001
Urate, mmol/l 0.47  0.14 0.40  0.12 0.44  0.13 0.49  0.14 0.53  0.15 <0.0001
HbA1c, % 6.3  1.3 6.1  1.2 6.3  1.3 6.4  1.3 6.5  1.5 0.049
Hemoglobin, g/l 12.5  2.0 13.3  2.0 12.7  2.0 12.5  1.8 11.7  1.9 <0.0001
White cell count,  109/l 7.9  2.4 8.0  2.9 7.8  1.9 7.8  2.2 8.1  2.5 0.511
RDW, % 15.6  2.5 15.0  2.0 15.7  2.6 15.5  2.2 16.2  2.9 <0.001
Lymphocytes,  109/l 1.9  1.3 2.2  2.2 1.8  0.7 1.8  0.7 1.7  0.8 0.007
Medical therapies
Diuretic 603  96.0 147  93.6 151  96.2 152  96.8 153  97.5 0.405
ACEI or ARB 501  79.8 134  85.4 129  82.2 120  76.4 118  75.2 0.077
MRA 84  13.4 21  13.4 19  12.1 22  14.0 22  14.0 0.955
Beta blocker 416  66.2 107  68.2 99  63.1 107  68.2 103  65.6 0.744
Values are mean  SD or median [interquartile range].
ACEI ¼ angiotensin-converting enzyme inhibitor; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide;
cFLC ¼ combined free light chains; COPD ¼ chronic obstructive pulmonary disease; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular ﬁltration rate; HBA1c ¼
glycosylated hemoglobin; HF ¼ heart failure; HR ¼ heart rate; hsCRP ¼ high-sensitivity C-reactive protein; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection
fraction; MI ¼ myocardial infarction; MRA ¼ mineralocorticoid receptor antagonist; NYHA ¼ New York Heart Association classiﬁcation; PAD ¼ peripheral arterial disease; Q ¼
quartile; RDW ¼ red cell distribution width; SBP ¼ systolic blood pressure.
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622UNADJUSTED OUTCOMES ACCORDING TO cFLC
CONCENTRATION. Patients with higher cFLC con-
centrations had higher mortality rates during the
follow-up period (Figure 1). There was a clear gradient
in the risk of death according to cFLC quartile (Q) with
the highest risk in patients with the highest cFLC
concentration. There were 55 (35%), 62 (39%), and 73
(46%) deaths among patients in Q1, Q2, and Q3,
respectively. Of 157 patients in the top quartile (Q4),
100 (64%) died, and the unadjusted risk of mortality
for these patients was more than twice that of those
in Q1 (hazard ratio [HR]: 2.38; p < 0.0001). Patients
were stratiﬁed according to BNP and cFLC concen-
tration using ROC curve cutoff values of 441 pg/ml
and 51.8 mg/l, respectively. Patients with low BNP
and low cFLC concentrations were at lowest risk of
mortality and patients with high BNP and high cFLC
concentrations were at greatest risk, whereas eleva-
tion of either biomarker was associated with an in-
termediate risk during follow-up (p < 0.0001)
(Figure 2).
When analyzed as a continuous variable, the
HR for all-cause mortality was 1.37 (95% conﬁdence
interval [CI]: 1.24 to 1.52) per SD of log cFLC per SD
(p < 0.001).Curves for All-Cause Mortality Stratiﬁed by
in Quartiles
es show an increasing gradient of risk with increasing quartile, with
uartile (Q4) having the highest mortality rates (p < 0.0001).
e light chain concentration.MULTIVARIABLE ANALYSIS INCLUDING cFLC
CONCENTRATION. Univariate and multivariable
analyses are shown in Table 2. The majority of var-
iables were signiﬁcant univariate predictors of
mortality. cFLC concentration was also a signiﬁcant
independent predictor of mortality (HR: 1.49;
p ¼ 0.01 for Q4 vs. Q1 to Q3) in the multivariable
analysis. Age, previous MI, NYHA III/IV, BMI, cur-
rent smoking and BNP, bilirubin, hsCRP, glycated
hemoglobin, and lymphocyte concentration were
also independent predictors of mortality. The
multivariable model was repeated with cystatin C
(data not shown), a more sensitive marker of renal
function, substituted for creatinine, and cFLC
remained an independent predictor of risk of death
(HR: 1.45; p ¼ 0.03).
The c-statistic for the model (with creatinine)
increased from 0.728 to 0.734 with the addition of
cFLC as Q1 to Q3 versus Q4 (p < 0.0001).
When analyzed as a continuous variable, the HR
for all-cause mortality was 1.17 (95% CI: 1.01 to 1.36)
per SD of log cFLC per SD (p ¼ 0.042). The c-statistic
increased from 0.728 to 0.730 (p < 0.0001).
NRI for the addition of cFLC (Q4 vs. Q1 to Q3)
to BNP (dichotomized according to ROC cutpoint
441 pg/ml) was high with an overall NRI of 0.439
(95% CI: 0.292 to 0.586; p < 0.0001). Compared with
the model using just BNP, the predicted probability of
an event (death) using the model with both BNP and
cFLCs was higher for 46.21% of patients with an event
and lower for the other 53.79%, resulting in an NRI of
-7.6% (95% CI: -19.1% to 3.9%; p ¼ 0.195) for those
patients who died. Using the same model, the pre-
dicted probability was lower for 75.74% of patients
who did not have an event (i.e., did not die) and
higher for the other 24.26%, resulting in an NRI of
51.5% (95% CI: 42.3% to 60.6%; p < 0.0001) for those
who survived. The overall NRI was therefore
43.9% (95% CI: 29.2% to 58.6%; p < 0.0001). Valida-
tion by bootstrap (300 replicates) resulted in an
optimism of 5%.
DISCUSSION
To our knowledge this is the ﬁrst study to describe
the prevalence and prognostic signiﬁcance of
elevated cFLC concentrations in a large group of
patients recently hospitalized with decompensated
HF. The ﬁrst notable ﬁnding was that almost one-
half of these patients had an elevated cFLC concen-
tration. The second important ﬁnding was that
patients with elevated cFLC concentrations were at
increased risk of death. Moreover, after adjustment
for other prognostic factors in a multivariable model,
FIGURE 2 Survival Curves for All-Cause Mortality Stratiﬁed According to Receiver
Operating Characteristic Curves for BNP and cFLC Concentrations
Kaplan-Meier analyses show patients with elevated BNP and elevated cFLC to be at
greatest risk, patients with low BNP and low cFLC at lowest risk, and patients with either
biomarker elevated to have an intermediate risk (p < 0.0001). BNP ¼ B-type natriuretic
peptide; cFLC ¼ combined free light chain concentration.
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dent predictor of mortality with a 30% higher
adjusted risk of death. The prognostic variables
prospectively included in the multivariable model
incorporated a comprehensive list of established
predictors of risk in HF (19–21). This list included
BNP, which is consistently found to be the most
powerful prognostic marker in HF and to which few,
if any, new markers add incremental predictive in-
formation. Furthermore, cFLC improved net reclas-
siﬁcation in addition to BNP.
CAUSE OF ELEVATED cFLCs IN HF. The cause of
elevated cFLCs in patients with HF is unknown. It
may reﬂect generalized immune system activation or
represent a more speciﬁc inﬂammatory response, as
seen in viral myocarditis (25). The hazard related to
increased cFLC concentration in the present study
was independent of hsCRP. Although several other
inﬂammatory biomarkers have also been shown to
have independent prognostic value in HF (e.g., serum
soluble ST2) (26), it may be that the mechanism un-
derlying cFLC elevation in HF may be more than just
simply generalized immune system activation. FLC
concentrations also reﬂect renal clearance, which
may be reduced in HF. However, the ability of this
biomarker to provide risk stratiﬁcation independent
of creatinine, and cystatin C, suggests that elevated
cFLCs is not simply a surrogate for reduced kidney
function. Our ﬁnding of elevated cFLCs also suggests
it may be of interest to study other B cellrelated
cytokines such as interleukin-6, B-lymphocyte stim-
ulator, and proliferation-inducing ligand in HF.
ASSOCIATION BETWEEN cFLCs AND PROGNOSIS.
There are a number of ways in which elevated FLCs
might be associated with worse prognosis. Elevated
FLCs may represent an immune response to endo-
toxins, which have entered the circulation through
a leaky intestinal tract, as is believed to occur in
patients with advanced HF and which may
contribute to progression of the syndrome through
cytokine activation and other inﬂammatory mech-
anisms. Alternatively, FLCs might reﬂect autoanti-
body production to myocyte proteins, as seen in
myocarditis and transplant rejection, or to beta-
adrenoceptors. FLCs may themselves have a direct
and adverse biological effect. FLCs are believed to
activate mast cells, which play a central role in the
inﬂammatory process (27), producing mediators
such as cytokines, which may have a deleterious
role in HF. Mast cells have been shown to cause
apoptosis of cardiac myocytes and proliferation of
non-myocardial cells in an animal model of HF and
increased mast cell density is recognized in heartswith left ventricular systolic dysfunction compared
with normal hearts (28,29). This study suggested
that the initial compensatory effect of the immune
system response might lead to cardiac remodeling
and ultimately progression of HF severity. Whether
or not a similar potential pathophysiological pro-
cess underlies chronic elevation of FLCs in HF is
unknown. On the other hand, it is also possible
that cFLCs may simply represent a non-speciﬁc
marker of widespread immune system activation,
rather than directly being involved in the patho-
genesis of HF.
POTENTIAL ROLE OF cFLCs IN THE MANAGEMENT
OF HF? cFLC measurement is a simple, readily
available blood test that identiﬁes patients at
increased mortality risk in this study. A single mea-
surement of cFLCs led to a signiﬁcant improvement
in net reclassiﬁcation but longitudinal monitoring of
this biomarker may be even more useful for risk
stratiﬁcation and identifying patients at particularly
high risk. However, the effect of disease progression
on cFLC concentrations is unknown.
The effects of HF therapies on cFLC concentrations
is unknown, as is the effect of immune modulating
TABLE 2 Univariate Analysis and Multivariable Model for All-Cause Mortality
Univariate Analysis
HR (95% CI); p Value
Multivariable Model
HR (95% CI); p Value
Clinical variables
Age, yrs, per SD 1.60 (1.40-1.83); <0.0001 1.42 (1.19-1.63); <0.001
Female 0.88 (0.70-1.12); 0.30 —
Current smoker 1.14 (0.87-1.50); 0.36 1.57 (1.12-2.19); 0.008
HF >2 yrs 1.50 (1.18-1.90); <0.001 —
NYHA functional class III/IV 1.83 (1.45-2.31); <0.0001 1.33 (1.02-1.73); 0.033
LVEF, per SD <50% 1.20 (1.07-1.34); 0.002 —
MI 1.75 (1.39-2.21); <0.0001 1.54 (1.19-2.00); 0.001
Diabetes mellitus 1.17 (0.92-1.50); 0.199 —
COPD 1.37 (1.07-1.75); 0.012 —
PAD 1.04 (0.76-1.42); 0.811 —
LBBB 1.51 (1.15-1.98); 0.003 —
HR, per SD 1.00 (0.88-1.12); 0.904 —
SBP, per SD 0.95 (0.84-1.06); 0.352 —
BMI, per SD <30 kg/m2 1.36 (1.22-1.52); <0.0001 1.24 (1.08-1.42); 0.002
Peripheral edema 1.38 (1.07-1.78); 0.013 —
Laboratory parameters
cFLC Q4 (vs. Q1-Q3) 1.97 (1.55-2.52); <0.0001 1.49 (1.09-2.03); 0.012
Log (BNP), per SD 1.62 (1.43-1.83); <0.0001 1.28 (1.10-1.49); 0.002
Bilirubin, per SD 1.29 (1.16-1.43); <0.0001 1.24 (1.10-1.41); <0.001
Urate, per SD 1.22 (1.09-1.37); <0.001 —
hsCRP, per SD 1.30 (1.18-1.42); <0.0001 1.19 (1.06-1.32); 0.003
Creatinine, per SD 1.19 (1.08-1.32); <0.001 —
Hemoglobin, per SD 0.80 (0.71-0.89); <0.0001 —
HbA1c, per SD 1.06 (0.95-1.19); 0.312 1.25 (1.07-1.46); 0.005
Log (lymphocytes), per SD 0.74 (0.66-0.82); <0.0001 0.84 (0.73-0.97); 0.019
Log (RDW), per SD 1.21 (1.10-1.34); <0.001 —
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Inﬂammatory pathways are recognized in the patho-
genesis and progression of HF. Increases in both
kappa and lambda FLCs occur in autoimmune and
other chronic inﬂammatory conditions. cFLCs are an
independent predictor of mortality in patients
recently hospitalized with decompensated HF.
TRANSLATIONAL OUTLOOK 1: Although an
isolated measurement of cFLCs identiﬁed patients at
greatest risk of death in this study, longitudinal
monitoring of this biomarker may be more useful for
risk stratiﬁcation and identifying patients at particu-
larly high risk.
TRANSLATIONAL OUTLOOK 2: The effects of HF
therapies and immune modulating treatments on cFLC
concentrations are unknown, but should be studied
as these may improve risk stratiﬁcation for patients
with HF.
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HF. Reduction in immunoglobulin G by immu-
noadsorption in a small randomized study (n ¼ 34) of
patients with nonischemic dilated cardiomyopathy
and b1-adrenoceptor autoantibodies was associated
with an improvement in LVEF compared with stan-
dard HF therapy (30). The effect on mortality was
not reported. Only 1 previous study has reported on
reduction in individual concentrations of kappa and
lambda FLCs in patients with HF. In this small trial
(n ¼ 59) of patients with advanced decompensated
HF, patients were randomized to receive levosi-
mendan or standard HF treatment (31). Those re-
ceiving levosimendan had a reduction in both kappa
and lambda FLC concentrations compared with those
receiving standard therapy. However, no outcome
data were reported. Whether or not therapeutic
reduction in cFLC concentrations in patients with HF
improves clinical outcomes is unknown but would
seem to be of interest given the results reported
herein.
STUDY LIMITATIONS. Only a single baseline measure-
ment of cFLC concentration was available for the patientsin this study. It is not knownwhether cFLC concentrations
change over time or in response to treatment in patients
withHF.Ourpatientswere studiedapproximately 1month
post-hospitalization for decompensated HF; cFLC levels
may differ between acutely decompensated and chroni-
cally stable patients (andourswas a survivor cohort).Non-
fatal outcomes, such as hospitalization for worsening HF,
and mode of death were not available. We did not have a
validation cohort.
CONCLUSIONS
cFLC concentration is an independent predictor of
mortality in patients recently hospitalized with
decompensated HF. This simple blood test is readily
available in clinical practice. Further work is required
to assess the role of cFLC level as a biomarker in HF,
including evaluation of the effects of HF treatment
and anti-inﬂammatory disease modifying therapies
on cFLC concentrations. Ultimately, it may be of in-
terest to test whether directly targeting this marker of
inﬂammation improves prognosis.
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